124 related articles for article (PubMed ID: 21828377)
21. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
22. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
Gietema JA; Veldhuis GJ; Guchelaar HJ; Willemse PH; Uges DR; Cats A; Boonstra H; van der Graaf WT; Sleijfer DT; de Vries EG
Br J Cancer; 1995 Jun; 71(6):1302-7. PubMed ID: 7779728
[TBL] [Abstract][Full Text] [Related]
23. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler DD; Guerciolini R; Williams PJ
Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
[TBL] [Abstract][Full Text] [Related]
28. Clinical and pharmacokinetic evaluation of satraplatin.
Doshi G; Sonpavde G; Sternberg CN
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):103-11. PubMed ID: 22098065
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Gallerani E; Bauer J; Hess D; Boehm S; Droege C; Jeckelmann S; Miani M; Herrmann R; Marsoni S; Sperka S; Sessa C
Acta Oncol; 2011 Oct; 50(7):1105-10. PubMed ID: 21184645
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
31. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
33. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
[TBL] [Abstract][Full Text] [Related]
35. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
36. Satraplatin. BMS 182751, BMY 45594, JM 216.
Drugs R D; 2002; 3(1):67-71. PubMed ID: 11881537
[No Abstract] [Full Text] [Related]
37. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
[TBL] [Abstract][Full Text] [Related]
38. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
40. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]